Galectin Therapeutics announces commencement of patient enrolment of the adaptively-designed Phase 2b/3 trial of Belapectin (GR-MD-02) in NASH cirrhosis
Galectin Therapeutics (USA) announced on June 30, 2020, the commencement of patient enrolment of the adaptively-designed Phase 2b/3 trial of Belapectin (R-MD-02) in NASH cirrhosis.
For detailed information, see the below URL.
Belapectin is a galectin-3 inhibitor. The compound used the STAMTM mouse model for non-clinical studies, and data showing the improvement of NASH and fibrosis in the STAMTM mouse model was published in PLoS ONE （https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083481).
In the future, we believe that further clinical trial results for Belapectin will provide evidence for the STAMTM mouse model as a clinically predictive NASH model.